Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Recruiting · NCT07315113 · Interventional (participants receive a specific treatment) · Lead sponsor: Nuvectis Pharma, Inc.
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Provide written informed consent.
- 18 years old or older.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.
- Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.
Exclusion criteria
- Subject's cancer has a known oncogenic driver alteration other than EGFR.
- Known EGFR mutations that cause resistance to osimertinib
- Known human epidermal growth factor receptor 2 (HER2) overexpression
- Any contraindications to treatment with osimertinib
Where it is running
6 locations listed across 6 US states.
- Maryland Oncology Hematology - Calverton, Maryland, United States
- Massachusetts General Hospital - Boston, Massachusetts, United States
- Willamette Valley Cancer Institute and Research Center - Eugene, Oregon, United States
- UPMC Hillman Cancer Center - Pittsburgh, Pennsylvania, United States
- NEXT Houston - Houston, Texas, United States
- NEXT Virginia - Fairfax, Virginia, United States